Literature DB >> 34711942

Prion-like properties of the mutant huntingtin protein in living organisms: the evidence and the relevance.

Melanie Alpaugh1,2, Hélèna L Denis1,2, Francesca Cicchetti3,4.   

Abstract

If theories postulating that pathological proteins associated with neurodegenerative disorders behave similarly to prions were initially viewed with reluctance, it is now well-accepted that this occurs in several disease contexts. Notably, it has been reported that protein misfolding and subsequent prion-like properties can actively participate in neurodegenerative disorders. While this has been demonstrated in multiple cellular and animal model systems related to Alzheimer's and Parkinson's diseases, the prion-like properties of the mutant huntingtin protein (mHTT), associated with Huntington's disease (HD), have only recently been considered to play a role in this pathology, a concept our research group has contributed to extensively. In this review, we summarize the last few years of in vivo research in the field and speculate on the relationship between prion-like events and human HD. By interpreting observations primarily collected in in vivo models, our discussion will aim to discriminate which experimental factors contribute to the most efficient types of prion-like activities of mHTT and which routes of propagation may be more relevant to the human condition. A look back at nearly a decade of experimentation will inform future research and whether therapeutic strategies may emerge from this new knowledge.
© 2021. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 34711942     DOI: 10.1038/s41380-021-01350-4

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  92 in total

1.  Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology.

Authors:  C A Gutekunst; S H Li; H Yi; J S Mulroy; S Kuemmerle; R Jones; D Rye; R J Ferrante; S M Hersch; X J Li
Journal:  J Neurosci       Date:  1999-04-01       Impact factor: 6.167

2.  Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington's disease patients.

Authors:  Edward J Wild; Roberto Boggio; Douglas Langbehn; Nicola Robertson; Salman Haider; James R C Miller; Henrik Zetterberg; Blair R Leavitt; Rainer Kuhn; Sarah J Tabrizi; Douglas Macdonald; Andreas Weiss
Journal:  J Clin Invest       Date:  2015-04-06       Impact factor: 14.808

3.  Mutant huntingtin is present in neuronal grafts in Huntington disease patients.

Authors:  Francesca Cicchetti; Steve Lacroix; Giulia Cisbani; Nicolas Vallières; Martine Saint-Pierre; Isabelle St-Amour; Ranna Tolouei; Jeremy N Skepper; Robert A Hauser; Diego Mantovani; Roger A Barker; Thomas B Freeman
Journal:  Ann Neurol       Date:  2014-06-06       Impact factor: 10.422

Review 4.  Genetics and neuropathology of Huntington's disease.

Authors:  Anton Reiner; Ioannis Dragatsis; Paula Dietrich
Journal:  Int Rev Neurobiol       Date:  2011       Impact factor: 3.230

5.  Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release.

Authors:  N R Jana; E A Zemskov; N Nukina
Journal:  Hum Mol Genet       Date:  2001-05-01       Impact factor: 6.150

6.  Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation.

Authors:  S W Davies; M Turmaine; B A Cozens; M DiFiglia; A H Sharp; C A Ross; E Scherzinger; E E Wanker; L Mangiarini; G P Bates
Journal:  Cell       Date:  1997-08-08       Impact factor: 41.582

7.  Mapping the human plasma proteome by SCX-LC-IMS-MS.

Authors:  Xiaoyun Liu; Stephen J Valentine; Manolo D Plasencia; Sarah Trimpin; Stephen Naylor; David E Clemmer
Journal:  J Am Soc Mass Spectrom       Date:  2007-04-24       Impact factor: 3.109

8.  Eukaryotic proteasomes cannot digest polyglutamine sequences and release them during degradation of polyglutamine-containing proteins.

Authors:  Prasanna Venkatraman; Ronald Wetzel; Motomasa Tanaka; Nobuyuki Nukina; Alfred L Goldberg
Journal:  Mol Cell       Date:  2004-04-09       Impact factor: 17.970

9.  Human-to-mouse prion-like propagation of mutant huntingtin protein.

Authors:  Iksoo Jeon; Francesca Cicchetti; Giulia Cisbani; Suji Lee; Endan Li; Jiwoo Bae; Nayeon Lee; Ling Li; Wooseok Im; Manho Kim; Hyun Sook Kim; Seung-Hun Oh; Tae-Aug Kim; Jung Jae Ko; Benoit Aubé; Abid Oueslati; Yun Joong Kim; Jihwan Song
Journal:  Acta Neuropathol       Date:  2016-05-24       Impact factor: 17.088

10.  Outcome of cell suspension allografts in a patient with Huntington's disease.

Authors:  Alexander Maxan; Sarah Mason; Martine Saint-Pierre; Emma Smith; Aileen Ho; Timothy Harrower; Colin Watts; Yen Tai; Nicola Pavese; Julie C Savage; Marie-Ève Tremblay; Peter Gould; Anne E Rosser; Stephen B Dunnett; Paola Piccini; Roger A Barker; Francesca Cicchetti
Journal:  Ann Neurol       Date:  2018-10-25       Impact factor: 10.422

View more
  1 in total

1.  Rhes protein transits from neuron to neuron and facilitates mutant huntingtin spreading in the brain.

Authors:  Uri Nimrod Ramírez-Jarquín; Manish Sharma; Neelam Shahani; Yuqing Li; Siddaraju Boregowda; Srinivasa Subramaniam
Journal:  Sci Adv       Date:  2022-03-23       Impact factor: 14.136

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.